Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

50.0%

3 terminated/withdrawn out of 6 trials

Success Rate

25.0%

-61.5% vs industry average

Late-Stage Pipeline

50%

3 trials in Phase 3/4

Results Transparency

200%

2 of 1 completed trials have results

Key Signals

1 recruiting2 with results

Enrollment Performance

Analytics

Phase 3

3(60.0%)

Phase 2

2(40.0%)

5Total

Phase 3(3)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT05171075Phase 3Terminated

A Study Comparing Abelacimab to Dalteparin in the Treatment of Gastrointestinal/Genitourinary Cancer and Associated VTE

Role: lead

NCT05712200Phase 3Recruiting

Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)

Role: lead

NCT05171049Phase 3Terminated

A Study Comparing Abelacimab to Apixaban in the Treatment of Cancer-associated VTE

Role: lead

NCT04755283Phase 2Active Not Recruiting

Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation

Role: lead

NCT05421533Terminated

Study in Atrial Fibrillation (AF) Patients at High Risk of Stroke

Role: lead

NCT04213807Phase 2Completed

A Dose-range Finding Study of MAA868 in Patients With Atrial Fibrillation

Role: lead

All 6 trials loaded